AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
- Post author:
- Post published:February 7, 2024
- Post category:uncategorized